Key Highlights

• ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million)

• Egetis' lead asset EMCITATE is the first and only approved treatment for peripheral thyrotoxicosis associated with MCT8 deficiency

• The Acquisition price represents a 27% premium to the 60-day volume-weighted average share price of Egetis

• EMCITATE has estimated peak sales potential exceeding $300 million in its approved indication, with Orphan Drug exclusivity and Patent protection into 2045

ANI Pharmaceuticals Inc(NASDAQ:ANIP), a diversified pharmaceutical company, announced on November 5, 2026, a recommended public offer to acquire Egetis Therapeutics AB, a commercial-stage pharmaceutical company focused on rare diseases, in a transaction valued at approximately SEK 5.6 billion, or approximately $560 million. The deal, unanimously recommended by the Egetis Board, aims to combine ANI's resources and rare disease infrastructure with Egetis' commercialization and clinical development capabilities.

Deal Structure and Valuation

The Offer Price of SEK 11.25 per share represents a 27% premium to the 60-day volume-weighted average price of Egetis shares. On an Enterprise value basis, the transaction values Egetis at approximately $434 million when adjusted for estimated proceeds from Egetis' sale of its Rare Pediatric Disease Priority Review Voucher.

The acquisition has received the support of Egetis shareholders controlling approximately 42% of the outstanding shares, and the Egetis Board has unanimously recommended that shareholders accept the offer. ANI plans to fund the acquisition using a combination of existing resources and committed financing.

EMCITATE: A First-in-Class Rare Disease Treatment

At the center of the acquisition is EMCITATE, Egetis' lead product. EMCITATE received approval from the European Commission on February 12, 2025, and from the U.S. Food and Drug Administration (FDA) on September 28, 2026, as the first and only approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.

MCT8 deficiency is a rare genetic disorder estimated to affect approximately 1 in 70,000 males. The condition results in abnormal thyroid hormone transport into cells, leading to peripheral thyrotoxicosis and severe neurological impairment. Until EMCITATE's approval, there was no approved therapy specifically targeting this condition.

ANI Pharmaceuticals estimates that EMCITATE has potential peak sales exceeding $300 million in its approved indication. The product benefits from both U.S. and EU Orphan Drug Exclusivity, providing meaningful market protection, along with patent protection extending into 2045. These protections give ANI a long runway to commercialize the therapy and build Market Share in a condition with no competitive approved treatments.

Strategic Fit with ANI's Rare Disease Platform

The acquisition aligns with ANI Pharmaceuticals' strategy to build out its rare disease portfolio. The company has established a track record in the rare disease space and views the Egetis acquisition as an opportunity to Leverage its existing infrastructure, commercial capabilities, and relationships to accelerate the global commercialization of EMCITATE.

By combining ANI's resources, rare disease expertise, and infrastructure with Egetis' commercialization and clinical development capabilities, the merged entity aims to expand patient access to EMCITATE across approved markets while exploring potential label expansions and lifecycle management opportunities.

The rare disease market has become an increasingly attractive segment of the pharmaceutical industry due to the orphan drug incentives, reduced competitive intensity, and pricing dynamics that characterize these therapies. For ANI, adding a first-in-class, recently approved rare disease product with long-duration exclusivity represents a significant portfolio enhancement.

Regulatory and Closing Considerations

The offer is subject to customary conditions, including regulatory approvals and the achievement of a minimum acceptance threshold from Egetis shareholders. Given the support of shareholders controlling approximately 42% of shares and the unanimous Board recommendation, the path to completion appears to be defined, though the timeline will depend on the acceptance period and regulatory review processes.

ANI noted that it plans to release its Q3 2026 Earnings results simultaneously with the acquisition announcement, demonstrating its intent to manage both the ongoing Business performance and the integration planning in parallel.

The Broader Picture

The Egetis acquisition positions ANI Pharmaceuticals as a more diversified rare disease player with a commercially validated first-in-class asset. The combination of EMCITATE's approved status in both the U.S. and Europe, its orphan drug protections, and the estimated peak sales potential above $300 million makes this transaction a potentially transformative addition to ANI's portfolio. Execution on the commercial launch and integration will be the key variables determining whether the deal delivers on its promise.